Cat. #160724
Caki-2 SETD2 KO cell line
Cat. #: 160724
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Kidney
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Sergio F de Almeida
Institute: Instituto de Medicina Molecular Jo?Âo Lobo Antunes
Tool Details
*FOR RESEARCH USE ONLY
- Name: Caki-2 SETD2 KO cell line
- Alternate name: HBP231, HIF-1, HIP-1, HYPB, KMT3A
- Tool sub type: Continuous
- Parental cell: Clear cell renal cell carcinoma cell line (Caki-2)
- Organism: Human
- Tissue: Kidney
- Model: Knock-Out
- Conditional: No
- Description: Experimental ablation of SETD2 gene expression using the CRISPR/Cas9 system renders Caki-2-SETD2 knockout cells a valuable tool to investigate the role of H3K36me3 histone methylation in processes such as transcription or DNA repair.
- Production details: CRISPR/Cas9 KO
- Additional notes: Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Ca...
- Recommended controls: Caki-2 Parental Line
Target Details
- Target: SET domain containing 2
Applications
- Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...
Handling
- Format: Frozen
- Growth medium: Grow as monolayers in Dulbecco's modified Eagle medium, supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/mL penicillin-streptomycin, at 37?°C in a humidified atmosphere with 5% CO2.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
Related Tools
- Related tools: Caki-2 DNMT3A KO cell line
References
- de Matos et al. 2019. Cancers (Basel). 11(3):. PMID: 30897760.
